(Q38046662)

27 August 2017

title

mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders (English)

1 reference

27 August 2017

main subject

autism spectrum disorder

0 references

0 references

1 reference

Lindsay M Oberman

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

26 September 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1819-1825

1 reference

The neurology of autism spectrum disorders

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Comorbid psychopathology with autism spectrum disorder in children: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Model of autism: increased ratio of excitation/inhibition in key neural systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Neocortical excitation/inhibition balance in information processing and social dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Syndromic autism: causes and pathogenetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Increased serum levels of glutamate in adult patients with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Plasma amino acid levels in children with autism and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Fragile x syndrome and autism: from disease model to therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The Autistic Neuron: Troubled Translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Alterations of GABAergic signaling in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Serotonin and amino acid content in platelets of autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Involvement of reelin and Cajal-Retzius cells in the developmental formation of vertical columnar structures in the cerebral cortex: evidence from the study of mouse presubicular cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Minicolumnar pathology in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Neuronal density and architecture (Gray Level Index) in the brains of autistic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pathways to drug development for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Suppression of LTP-like plasticity in human motor cortex by the GABAB receptor agonist baclofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

10.1517/13543784.2012.729819

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference